Observational study identifies five metabolic dysfunction-associated liver disease subtypes and associated risks — Evidence Review
Published in Nature Communications, by researchers from Mayo Clinic, Virginia Tech
Researched by
— the AI search engine for science
Table of Contents
A new study has identified five biologically distinct subtypes of metabolic dysfunction-associated steatotic liver disease (MASLD), suggesting the condition is more heterogeneous than previously recognized. Related studies generally agree that MASLD is a complex, multifaceted disease, but previous work typically recognized only two major types rather than five; this new research from Mayo Clinic adds important detail to our understanding of MASLD subtypes.
- Earlier studies have established that MASLD and its related forms carry an increased risk of cardiovascular and liver-related complications, but have largely grouped patients into broader categories based on clinical or genetic factors, whereas this study identifies five subtypes with distinct risk profiles 1 2 3 5.
- Prior research using genetic and cluster analysis typically identified two main MASLD types—one with liver-specific genetic risk and another with systemic cardiometabolic risk; the new findings expand this to five subtypes, revealing greater heterogeneity in disease mechanisms and progression 3 5.
- The focus on genetic subtypes with higher risk, even among those lacking traditional metabolic risk factors, builds upon and deepens earlier observations regarding the importance of fibrosis stage and genetic risk in predicting outcomes for MASLD patients 2 11.
Study Overview and Key Findings
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), affects nearly a third of adults worldwide and is a leading cause of liver-related morbidity and mortality. Its clinical course is highly variable, with some patients experiencing slow progression and others advancing rapidly to liver failure or cancer. Despite this heterogeneity, most clinical approaches have treated MASLD as a single disease entity. This study leverages large-scale genomic and clinical data to uncover hidden patterns of disease progression and stratify patients into biologically meaningful subgroups.
The research, conducted by Mayo Clinic in collaboration with Virginia Tech, analyzed over 4,600 MASLD patients using advanced computational modeling and genetic sequencing. The team identified five distinct subtypes, each associated with different biological pathways and health risks—not only for liver disease but also for conditions such as cardiovascular disease, depression, and sleep apnea. These findings could pave the way for more personalized approaches to screening and treatment.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Mayo Clinic, Virginia Tech |
| Journal Name | Nature Communications |
| Authors | Tahmina Sultana Priya, Huihuang Yan, Kirk J. Wangensteen, Stephen Wu, Anthony C. Luehrs, Filippo Pinto e Vairo, Fan Leng, Andres J. Acosta, Robert A. Vierkant, Alina M. Allen, Konstantinos N. Lazaridis, Eric W. Klee, Danfeng Daphne Yao, Shulan Tian |
| Population | Patients with metabolic dysfunction-associated steatotic liver disease |
| Sample Size | n=4600 |
| Methods | Observational Study |
| Outcome | Identification of distinct subtypes of MASLD and associated risks |
| Results | Five MASLD subtypes linked to different health risks were identified. |
Literature Review: Related Studies
To contextualize these findings, we searched the Consensus paper database, which contains over 200 million research papers. The following search queries were used to identify relevant literature:
Summary Table of Key Topics and Findings
| Topic | Key Findings |
|---|---|
| How heterogeneous is MASLD, and what subtypes exist? | - Recent studies identify two main MASLD subtypes: one genetically driven and liver-specific, another cardiometabolic and systemic, but the new study expands this to five, suggesting even greater biological diversity 3 5. - The use of polygenic risk scores and clustering analyses supports the existence of biologically and clinically meaningful subgroups 3 5. |
| What are the major health risks associated with MASLD? | - MASLD is consistently linked to increased cardiovascular disease (CVD) risk, with hazard ratios noted across large cohorts 1 4. - Advanced fibrosis stage is the strongest predictor of liver-related complications and mortality among MASLD patients 2 11. |
| How prevalent is MASLD globally, and what drives its increase? | - MASLD/NAFLD affects 30–35% of adults globally, with higher prevalence in men and in populations with obesity or diabetes 6 8 9 10. - Rising prevalence is closely tied to increases in obesity and type 2 diabetes, particularly in Western and high-income nations 7 10 12 14. |
| How do genetic and metabolic factors influence MASLD outcomes? | - Genetic variants can drive aggressive liver disease even in the absence of classic metabolic risk factors, while metabolic dysfunction increases both liver and cardiovascular risks 3 5 11. - Existing risk stratification tools focus mainly on fibrosis, but additional genetic and clinical markers are needed 2 5. |
How heterogeneous is MASLD, and what subtypes exist?
Previous research has generally recognized MASLD as a heterogeneous condition, but most studies have identified only two primary subtypes—one driven by liver-specific genetic variants and another associated with broader cardiometabolic dysfunction. The new study's identification of five subtypes reveals a more complex spectrum of disease mechanisms than previously understood, indicating that MASLD comprises multiple distinct biological pathways.
- Earlier cluster and genetic analyses found two main MASLD types: a genetically driven, liver-centric subtype and a systemic, cardiometabolic subtype 3 5.
- The new study extends these findings by identifying five distinct subtypes, each with unique biological and clinical characteristics 3 5.
- Polygenic risk scores and machine learning methods are increasingly used to tease apart these subgroups and their associated risks 3 5.
- This expanded classification may improve the precision of risk prediction and treatment selection for MASLD patients 3 5.
What are the major health risks associated with MASLD?
MASLD is associated with a range of adverse health outcomes, particularly cardiovascular disease and liver-related complications. Large cohort studies have demonstrated that individuals with MASLD are at elevated risk for heart disease, stroke, and liver-related morbidity and mortality. The severity of liver fibrosis is the strongest predictor of death and hepatic complications.
- MASLD increases the risk of cardiovascular events, with hazard ratios ranging from 1.19 to 1.39 in large population studies 1 4.
- Advanced fibrosis (stages F3–F4) is linked to higher rates of liver-related complications and all-cause mortality 2 11.
- MASLD patients also face increased risk of extrahepatic conditions, including certain cancers and renal dysfunction 2 11 13.
- The new study's finding that certain MASLD subtypes are associated with depression, sleep apnea, and migraine broadens the spectrum of recognized comorbidities [new study].
How prevalent is MASLD globally, and what drives its increase?
The global prevalence of MASLD/NAFLD is estimated at about 30–35% among adults, with higher rates in men and in populations with elevated rates of obesity and diabetes. Prevalence has increased over recent decades, mirroring trends in body mass index and metabolic syndrome, particularly in Western countries.
- Meta-analyses and national surveys find MASLD/NAFLD prevalence ranging from 27% to over 38%, with increases over time 6 8 9 10.
- Prevalence is particularly high among overweight and obese adults, exceeding 50% in some groups 8.
- The rise in MASLD/NAFLD prevalence is closely linked to growing rates of obesity and type 2 diabetes 7 10 12.
- These trends underscore the urgent need for improved screening and risk stratification tools 6 10 14.
How do genetic and metabolic factors influence MASLD outcomes?
Genetic variants and metabolic dysfunction both significantly impact MASLD progression and outcomes. Some patients with genetic risk factors develop severe liver disease even without traditional metabolic risks, while those with metabolic syndrome are at higher risk for both liver and cardiovascular complications. Current risk stratification protocols rely heavily on fibrosis stage, but integrating genetic data may improve predictive accuracy.
- Genetic risk factors can cause rapid progression to advanced liver disease, sometimes independent of metabolic syndrome 3 5.
- Polygenic risk scores separate MASLD into types with differing clinical trajectories and risks 5.
- Fibrosis stage remains the most robust predictor of mortality, but genetic and metabolic markers could further refine risk stratification 2 5 11.
- The new study's identification of genetic MASLD subtypes aligns with these findings, suggesting a need for more individualized approaches to management [new study].
Future Research Questions
While the identification of five distinct MASLD subtypes marks a substantial advance, further research is needed to validate these subtypes in diverse populations, clarify their molecular underpinnings, and assess their implications for clinical practice. Key areas for future investigation include the development of targeted therapies, improved risk stratification, and the study of comorbid conditions associated with specific MASLD subtypes.
| Research Question | Relevance |
|---|---|
| How do the five MASLD subtypes respond to different therapies? | Understanding subtype-specific treatment responses could enable precision medicine approaches and improve outcomes, especially as current therapies may not be equally effective across all subgroups 2 3 5. |
| Can the five MASLD subtypes be validated in diverse populations and ethnicities? | Most studies, including the current one, are conducted in specific populations; external validation is essential to ensure broad applicability and address health disparities 6 9 15. |
| What molecular and genetic pathways distinguish each MASLD subtype? | Detailed molecular characterization will clarify the mechanisms driving each subtype, potentially revealing new therapeutic targets and biomarkers for early detection 3 5. |
| How do MASLD subtypes influence the risk of extrahepatic diseases such as CVD, depression, and sleep apnea? | The new study reports associations with non-liver conditions, but further research is needed to understand these relationships and their clinical implications 1 2 13. |
| Can integrating genomic and clinical data improve MASLD risk stratification beyond fibrosis stage? | Current risk models focus on fibrosis, but adding genetic and clinical subtype information may refine predictions of disease progression and mortality 2 5 11. |
This article synthesizes current knowledge on MASLD subtypes, prevalence, and associated health risks, highlighting the need for further research into personalized approaches to diagnosis, risk prediction, and treatment.